A business in context

ACXP research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 8-K · Current report

    Report date 2026-10-16 · 0001104659-26-116632 · Items 5.07

  2. DEF 14A · Proxy statement

    Report date 2026-10-16 · 0001104659-26-104316

  3. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001104659-26-095904

  4. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001104659-26-058631

  5. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046846

  6. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046844

  7. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046842

  8. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046840

  9. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046837

  10. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046836

  11. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046835

  12. 4 · Ownership change

    Report date 2026-04-20 · 0001104659-26-046833

  13. 8-K · Current report

    Report date 2026-04-15 · 0001104659-26-044093 · Items 1.01,3.02,8.01,9.01

  14. 10-K · Annual report

    Report date 2025-12-31 · 0001104659-26-027052

  15. 8-K · Current report

    Report date 2026-03-09 · 0001104659-26-025003 · Items 5.02,8.01,9.01

  16. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001104659-25-109698

  17. 8-K · Current report

    Report date 2025-09-22 · 0001104659-25-092166 · Items 5.03,9.01

  18. 8-K · Current report

    Report date 2025-09-16 · 0001104659-25-091733 · Items 5.07

  19. 10-Q · Quarterly report

    Report date 2025-06-30 · 0001558370-25-011045

  20. DEF 14A · Proxy statement

    Report date 2025-09-16 · 0001104659-25-073623

  21. 8-K · Current report

    Report date 2025-07-31 · 0001104659-25-072529 · Items 3.03,5.03,8.01,9.01

  22. 8-K · Current report

    Report date 2025-07-17 · 0001104659-25-068659 · Items 5.07

  23. 8-K · Current report

    Report date 2025-06-17 · 0001104659-25-060902 · Items 1.01,3.02,8.01,9.01

  24. DEF 14A · Proxy statement

    Report date 2025-07-17 · 0001104659-25-054235

  25. 8-K · Current report

    Report date 2025-05-13 · 0001104659-25-047566 · Items 2.02,9.01

  26. 10-Q · Quarterly report

    Report date 2025-03-31 · 0001558370-25-007371

  27. 8-K · Current report

    Report date 2025-05-08 · 0001104659-25-046167 · Items 1.01,3.02,9.01

  28. 8-K · Current report

    Report date 2025-03-25 · 0001104659-25-029370 · Items 3.01

  29. 8-K · Current report

    Report date 2025-03-18 · 0001104659-25-024731 · Items 2.02,9.01

  30. 10-K · Annual report

    Report date 2024-12-31 · 0001558370-25-003117

  31. 8-K · Current report

    Report date 2025-03-06 · 0001104659-25-021978 · Items 1.01,3.02,8.01,9.01

  32. 8-K · Current report

    Report date 2025-02-24 · 0001104659-25-017437 · Items 3.01

  33. 8-K · Current report

    Report date 2025-01-06 · 0001104659-25-001586 · Items 1.01,3.02,8.01,9.01

  34. 8-K · Current report

    Report date 2024-11-13 · 0001104659-24-117214 · Items 2.02,9.01

  35. 10-Q · Quarterly report

    Report date 2024-09-30 · 0001558370-24-015310

  36. 8-K · Current report

    Report date 2024-08-09 · 0001104659-24-087545 · Items 2.02,9.01

  37. 10-Q · Quarterly report

    Report date 2024-06-30 · 0001558370-24-011587

  38. 8-K · Current report

    Report date 2024-06-17 · 0001104659-24-072270 · Items 5.07

  39. 8-K · Current report

    Report date 2024-05-15 · 0001104659-24-061579 · Items 2.02,9.01

  40. 10-Q · Quarterly report

    Report date 2024-03-31 · 0001558370-24-008130

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 0 transaction rows0SGrant / award: 0 transaction rows0AExercise / conversion: 0 transaction rows0MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

0 matching transaction rows.

No matching transaction rows in the covered quarter. This does not establish that no insider transactions occurred.

Identity & relationships

Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001736243Acurx Pharmaceuticals, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records

Search names and former names
  • Acurx Pharmaceuticals, LLC · former SEC name · 2018-04-03 to 2021-06-23

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing

Explore the CPI history ↗